Fox Run Management’s AngioDynamics ANGO Stock Holding History

Fox Run Management’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,468	Closed	-$145K	–	844
2025 Q1	$145K	Buy	+15,468	New	+$163K	0.02%	835
2023 Q4	–	Sell	-10,657	Closed	-$77.9K	–	712
2023 Q3	$77.9K	Sell	10,657 -5,505	-34%	-$45.8K	0.02%	643
2023 Q2	$169K	Buy	+16,162	New	+$156K	0.05%	601

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's ANGO Position: Q2 2025 in Review

Fox Run Management sold out of AngioDynamics (ANGO) in Q2 2025, closing a stake of 15,468 shares — an estimated $145K sold.

Fox Run Management first reported a position in ANGO in Q2 2023 and held it in 3 quarters. The position peaked at $169K in Q2 2023. 150 funds tracked by Wall St. Rank hold ANGO as of Q2 2025.

Fox Run Management reported no remaining AngioDynamics position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 15,468 AngioDynamics shares in Q2 2025, an estimated $145K.
Fox Run Management first reported a position in AngioDynamics in Q2 2023 and held it in 3 quarters.
Fox Run Management's AngioDynamics position peaked at $169K in Q2 2023.
150 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.